Marie Sherlock (Dublin Central, Labour)
Link to this: Individually | In context | Oireachtas source

280. To ask the Minister for Health if her Department intends on including mandatory breast density notification within the BreastCheck Programme; and if she will make a statement on the matter. [17960/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I am committed to supporting our population screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people, and improving the overall health of our population.

BreastCheck, the National Breast Screening Programme, currently invites women aged 50 to 69 years at regular periods to have a mammogram. The current Programme for Government also commits to further extend the BreastCheck programme.

I am intent on advancing cancer screening commitments outlined in the Programme for Government, which will be facilitated through established protocols. The National Screening Advisory Committee (NSAC) is the independent expert group that considers proposed changes to Ireland’s screening programmes. NSAC assesses the evidence in a robust and transparent manner, and against internationally accepted criteria, before making recommendations to myself as Minister for Health. The rigorous processes utilised by NSAC are critical to ensure that our screening programmes are effective, quality assured and operating to safe standards, and that the benefits of screening outweigh the harms.

In this regard, I am pleased to report that NSAC is progressing work to consider the further expansion of our cancer screening programmes and has submitted a request to the Health Information and Quality Authority (HIQA), which has a section dedicated to undertaking evidence synthesises on behalf of the Committee, to assess the evidence for a further expansion of the BreastCheck programme. The review will focus on two key elements, the expansion of the age range eligibility and the potential introduction of a standardised breast density measurement. This work is expected to start later this year.

HIQA is currently focused on two Health Technology Assessment (HTA) processes underway to examine the expansion of the BowelScreen programme and the potential development of a population-based screening programme for Abdominal Aortic Aneurism (AAA). The evidence review for the expansion of BreastCheck remains a key priority for NSAC and is expected to commence once the ongoing HTAs have concluded.

HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multi-disciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology. They are time intensive and rigorous processes. Both elements of the BreastCheck review are anticipated to be complex and will take time to ensure that any recommendations made to me by NSAC are underpinned by a robust evidence-basis.

Significant investment continues to be made in our national screening programmes. This includes allocating an additional €2.9 million in full-year costs to BreastCheck for 2025. This funding will help to future-proof the programme, allowing for increased capacity and enabling service developments to meet women's evolving needs and ensure equitable access across the entire population.

Finally, I would like to emphasise that population-based screening programmes are for people without symptoms. If anyone becomes aware of symptoms, or if they have concerns or worries, they should contact a medical professional.